ARTICLE | Company News
QLT, Advanced Ocular deal
May 29, 2006 7:00 AM UTC
QLT received an exclusive option to license AOS’s rapamycin-based technology to treat ophthalmic diseases. If QLT exercises the option, AOS will receive up to $3.5 million in option fees and milestone...